FDA Authorizes Booster Dose of Pfizer COVID-19 Vaccine

2021-09-23 |

9/23/21 -- The FDA amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series in:

  • individuals 65 years of age and older;
  • individuals 18 through 64 years of age at high risk of severe COVID-19; and
  • individuals 18 through 64 years of age whose frequent institutional or occupational exposure to SARS-CoV-2 puts them at high risk of serious complications of COVID-19 including severe COVID-19.

This authorization applies only to the Pfizer-BioNTech COVID-19 Vaccine. Read the FDA announcement.